The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2.
Cathcart AL, Havenar-Daughton C, Lempp FA, et al. bioRxiv. 2021. [Epub ahead of print]
Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial.
Cohen MS, Nirula A, Mulligan MJ, et al. JAMA. 2021;326(1):46-55
Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa.
Davies MA, Kassanjee R, Rosseau P, et al. medRxiv. 2022. [Epub ahead of print]
Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2.
Di Fusco M, Moran MM, Cane A, et al. J Med Econ. 2021;24(1):1248-1260.
Safety and efficacy of combination SARS-CoV-2 monoclonal neutralizing antibodies BRII-196 and BRII-198 in non-hospitalized COVID-19 patients.
Evering T. IDWeek; September 29-October 3, 2021. Virtual conference.
Haynes N, Cooper LA, Albert MA. Circulation. 2020;142(2):105-107.
PROVENT: Phase 3 study of efficacy and safety of AZD7442 (tixagevimab/cilgavimab) for pre-exposure prophylaxis of COVID-19 in adults.
Levin M, et al. IDWeek; September 29-October 3, 2021. Virtual conference.
AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans.
Loo Y-M, McTamney PM, Arends RH, et al. medRxiv. 2021.08.30.21262666.
O’Brien MP, Forleo-Neto E, Musser BJ, et al. N Engl J Med. 2021. [Epub ahead of print].
Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment and Prevention
|Faculty:||Onyema Ogbuagu, MBBCh, FACP, FIDSA|